Le Lézard
Classified in: Health
Subject: IMA

ER-REBOA PLUStm Catheter Earns UK and CE Mark Approval


BOERNE, Texas, May 24, 2021 /CNW/ -- Prytime Medical Devices, Inc. announced today it has received both UK and CE Mark Approval for its next-generation ER-REBOA PLUStm Catheter. Designed for improved ease of use, this catheter replaces the market defining ER-REBOAtm catheter and represents an important evolution of REBOA technology. The new catheter is REBOA Refined for controlling non-compressible truncal hemorrhage.

"With this milestone, the new and improved ER-REBOA PLUStm Catheter will now be available for patients in the UK and Europe in addition to our previous approvals in the US and Canada," said Andrew Holman, CCO at Prytime Medical. "REBOA interest in the global trauma community continues to grow, so we work hard to continue to bring industry best solutions to physicians world-wide. We are pleased the next-generation ER-REBOA PLUStm Catheter is available to our expanding global community of users."

The ER-REBOA PLUStm Catheter maintains all the critical features of its namesake predecessor, including the only integrated arterial line for monitoring above-balloon blood pressure available on the market, industry leading on-label guidewire free and image free placement, low-profile 7Fr sheath compatibility, and patented atraumatic P-tiptm to aid in positioning. Important new features of the ER-REBOA PLUStm include a pre-captured balloon for ease of use, dual-sided length and zone markers, and a "leave behind" guidewire capability up to 0.025" to support transition to subsequent endovascular procedures.

"UK and CE Mark approval for ER-REBOA PLUStm is another important milestone for Prytime Medical," said David Spencer, CEO, Prytime Medical. "Our mission is to deliver state of the art minimally invasive solutions for hemorrhage control, so we will continue to innovate and expand access to our life-saving technology around the world."

To learn more about Prytime Medicaltm and the ER-REBOA PLUStm Catheter, visit www.prytimemedical.com, email [email protected] or call +1 (210) 340-0116.

About Prytime Medical Devices, Inc.
Prytime Medicaltm Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control. In trauma, hemorrhage is the leading cause of potentially survivable death. Non-compressible truncal hemorrhage is of particular interest, because of the limited clinical options available to stop bleeding prior to surgery. The underlying intellectual property for the original ER-REBOAtm technology was conceived by experienced military vascular surgeons, based on lessons learned in war. The new ER-REBOAtm PLUS Catheter represents an important evolution of REBOA and includes several new convenience features based on experience and input from civilian trauma surgeons from around the world.

Contact:

Julie Acosta


210-340-0116


[email protected]

 

SOURCE Prytime Medical


These press releases may also interest you

at 19:32
Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy...

at 19:21
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug...

at 18:30
Cannabix Technologies Inc. (the "Company or Cannabix") reports that it has entered into an arm's length marketing agreements with the following parties: Effective May 13, 2024, the Company has engaged Financial Buzz Media Networks LLC ("FBMN") for...

at 18:25
It is with great pleasure that we announce the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks...

at 18:03
Kelyniam Global , a maker of custom cranial implants, today announced results for its quarter ended March 31, 2024.  Financial highlights for the three months ended March 31, 2024 and the same period in 2023 include:  Total revenue of $957,447...

at 17:56
American Skin Association (ASA) is thrilled to announce that the SPOTS (Sun Protection Outreach Teaching by Students) program will receive the inaugural 2024 Research Achievement Award in Community Education/Outreach at the 2024 Society for...



News published on and distributed by: